Ascendiant Capital Markets Forecasts RenovoRx Q1 Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Ascendiant Capital Markets lifted their Q1 2026 earnings per share estimates for shares of RenovoRx in a report released on Wednesday, April 8th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.08). Ascendiant Capital Markets currently has a “Buy” rating and a $13.50 target price on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.40) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s Q3 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.26) EPS and FY2027 earnings at ($0.23) EPS.

Several other analysts also recently issued reports on RNXT. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of RenovoRx in a report on Wednesday, April 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of RenovoRx in a report on Monday, December 29th. JonesTrading raised shares of RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. Finally, Wall Street Zen cut shares of RenovoRx from a “hold” rating to a “strong sell” rating in a report on Saturday, April 4th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.25.

RenovoRx Stock Down 1.0%

Shares of RNXT stock opened at $1.02 on Wednesday. RenovoRx has a 12 month low of $0.70 and a 12 month high of $1.45. The company has a market cap of $45.95 million, a PE ratio of -3.19 and a beta of 1.22. The business’s 50 day moving average is $0.95 and its two-hundred day moving average is $0.99.

RenovoRx (NASDAQ:RNXT) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.42 million. RenovoRx had a negative return on equity of 119.77% and a negative net margin of 994.48%.During the same period last year, the business earned ($0.40) EPS.

Institutional Investors Weigh In On RenovoRx

Several hedge funds have recently modified their holdings of RNXT. AIGH Capital Management LLC increased its position in RenovoRx by 8.4% during the fourth quarter. AIGH Capital Management LLC now owns 2,833,894 shares of the company’s stock worth $2,380,000 after acquiring an additional 218,701 shares during the period. Bleichroeder LP boosted its holdings in RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after purchasing an additional 61,379 shares during the period. Geode Capital Management LLC boosted its holdings in RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after purchasing an additional 31,730 shares during the period. Wealthspire Advisors LLC acquired a new stake in RenovoRx in the 4th quarter worth $212,000. Finally, Citadel Advisors LLC bought a new position in shares of RenovoRx during the 3rd quarter worth about $154,000. 3.10% of the stock is owned by institutional investors.

More RenovoRx News

Here are the key news stories impacting RenovoRx this week:

• Positive Sentiment: Ascendiant Capital Markets raised several near-term EPS forecasts (Q1 & Q3 2026, FY2026, and FY2027) and issued model updates across 2026–2027 while keeping a “Buy” rating and a $13.50 price target — a clear analyst catalyst that can attract buyers and increase upside expectations. Ascendiant research / MarketBeat
• Positive Sentiment: Clinical data for RNXT’s TAMP™ platform was presented at the 2026 SIR Annual Scientific Meeting showing targeted local delivery of gemcitabine with reduced systemic toxicity in locally advanced pancreatic cancer patients — this could de-risk the program and support future regulatory/partnering value if results hold up. GlobeNewswire
• Neutral Sentiment: Ascendiant published multiple quarterly/annual line-item forecasts across 2026–2027 (detailed Q1–Q4 2026–2027 EPS assumptions). That expands coverage and provides a clearer benchmark for investors, but these are analyst-driven forecasts rather than company guidance. Ascendiant research / MarketBeat
• Negative Sentiment: Fundamentals remain weak: consensus full-year EPS still shows a loss (around -$0.40), and the company reported a recent quarter with a revenue shortfall versus estimates and very negative margins — ongoing losses and low revenue increase dilution/funding risk and limit near-term upside absent major clinical or financing news. Recent earnings / MarketBeat

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.